The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression
Abstract
Although in vitro sensitization assays have shown increased melanoma Ag (MA)-specific CTL reactivity after vaccination with MA peptides, clinical responses have been uncommon. This paradox questions whether data obtained from the in vitro stimulation and expansion of T cells lead to an overestimation of the immune response to vaccines. Using HLA/peptide tetramer (tHLA), we enumerated MA-specific T cell precursor frequency (TCPF) directly in PBMC from 23 melanoma patients vaccinated with gp100:209–217(210M) (g209–2M) peptide. Vaccine-specific TCPF was higher in postvaccination PBMC from seven of seven patients treated with peptide alone and four of five patients treated with peptide plus IL-12 (range of postvaccination TCPF, 0.2–2.4% and 0.2–2.5%, respectively). The increased TCPF correlated with enhanced susceptibility to in vitro stimulation with the relevant epitope. Paradoxically, no increase in postvaccination TCPF was observed in most patients who had been concomitantly treated with IL-2 (1 of 11 patients; range of postvaccination TCPF, 0.02–1.0%), a combination associated with enhanced rates of tumor regression. The lack of increase in TCPF seen in these patients corresponded to inability to elicit expansion of vaccine-specific T cells in culture. This study shows that a peptide-based vaccine can effectively generate a quantifiable T cell-specific immune response in the PBMC of cancer patients, though such a response does not associate with a clinically evident regression of metastatic melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 3×
“Tetrameric HLA/ peptide complexes (tHLA) allow for direct measurement of epitope-specific T cell precursor frequency (TCPF) without in vitro manipulation ( 7 ).”
BackgroundInfluentialRosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Self-citationQuantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA
Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M. A., Monard, S., Segal, J. P., Cao, Y., Rowland-Jones, S. L., Cerundolo, V., et al. (1998) · Science · doi:10.1126/science.279.5359.2103 · Cited by 1,383
Moskophidis, D., Lechner, F., Pircher, H., & Zinkernagel, R. M. (1993) · Nature · doi:10.1038/362758a0 · Cited by 1,240
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Bunce, M., O'Neill, C. M., Barnardo, M. C. N. M., Krausa, P., Browning, M. J., Morris, P. J., & Welsh, K. I. (1995) · Tissue Antigens · doi:10.1111/j.1399-0039.1995.tb03127.x · Cited by 997
Homeostasis and Self-Tolerance in the Immune System: Turning Lymphocytes off
Parijs, L. V., & Abbas, A. K. (1998) · Science · doi:10.1126/science.280.5361.243 · Cited by 965
Callan, M. F. C., Tan, L., Annels, N., Ogg, G. S., Wilson, J. D. K., O'Callaghan, C. A., Steven, N., McMichael, A. J., & Rickinson, A. B. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1395 · Cited by 892 · cited 1×
“measure T cell responses to viral infections (8, 9) and has been”
BackgroundDutton, R. W., Bradley, L. M., & Swain, S. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.201 · Cited by 832
Matzinger, P. (1998) · Seminars in Immunology · doi:10.1006/smim.1998.0143 · Cited by 748
Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., & Kawakami, Y. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.6.2539 · Cited by 556
Self-citationTumor antigens recognized by T cells
Boon, T., Coulie, P. G., & Van den Eynde, B. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80020-5 · Cited by 537
Romero, P., Rod Dunbar, P., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J.-L., Liénard, D., Cerottini, J.-C., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1641 · Cited by 521
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.
Topalian, S. L., Solomon, D., & Rosenberg, S. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.10.3714 · Cited by 512
Self-citationA Re-Evaluation of the Frequency of CD8+ T Cells Specific for EBV in Healthy Virus Carriers
Tan, L. C., Gudgeon, N., Annels, N. E., Hansasuta, P., O’Callaghan, C. A., Rowland-Jones, S., McMichael, A. J., Rickinson, A. B., & Callan, M. F. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1827 · Cited by 499
High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo
Ogg, G. S., Rod Dunbar, P., Romero, P., Chen, J.-L., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.6.1203 · Cited by 460
Effros, R. B., Allsopp, R., Chiu, C.-P., Hausner, M. A., Hirji, K., Wang, L., Harley, C. B., Villeponteau, B., West, M. D., & Giorgi, J. V. (1996) · AIDS · doi:10.1097/00002030-199607000-00001 · Cited by 457
New Paths in Human Cancer Serology
Old, L. J., & Chen, Y.-T. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1163 · Cited by 446
Cancer vaccines based on the identification of genes encoding cancer regression antigens
Rosenberg, S. A. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)84664-6 · Cited by 386
Self-citationReplicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion?
Effros, R. B., & Pawelec, G. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01079-7 · Cited by 336
Vitiello, A., Ishioka, G., Grey, H. M., Rose, R., Farness, P., LaFond, R., Yuan, L., Chisari, F. V., Furze, J., & Bartholomeuz, R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117662 · Cited by 334
Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., & Kast, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7855 · Cited by 292
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., & Marincola, F. M. (1997) · PubMed · Cited by 277
Self-citationGray, C. M., Lawrence, J., Schapiro, J. M., Altman, J. D., Winters, M. A., Crompton, M., Loi, M., Kundu, S. K., Davis, M. M., & Merigan, T. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1780 · Cited by 270
Kuroda, M. J., Schmitz, J. E., Barouch, D. H., Craiu, A., Allen, T. M., Sette, A., Watkins, D. I., Forman, M. A., & Letvin, N. L. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1373 · Cited by 262
Reversal of Tumor-Induced Immunosuppression: A New Approach to Cancer Therapy
Wojtowicz-Praga, S. (1997) · Journal of Immunotherapy · doi:10.1097/00002371-199705000-00001 · Cited by 240
Alexander-Miller, M. A., Leggatt, G. R., Sarin, A., & Berzofsky, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.485 · Cited by 222
Salgaller, M. L., Marincola, F. M., Cormier, J. N., & Rosenberg, S. A. (1996) · PubMed · Cited by 208
Self-citationToes, R. E., Blom, R. J., Offringa, R., Kast, W. M., & Melief, C. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3911 · Cited by 208
Alterations in T cell receptor and signal transduction molecules in melanoma patients.
Zea, A. H., Curti, B. D., Longo, D. L., Alvord, W. G., Strobl, S., Mizoguchi, H., Creekmore, S. P., O’Shea, J. J., Powers, G. C., & Urba, W. J. (1995) · PubMed · Cited by 190
Krausa, P., Brywka, M., Savage, D. A., Hui, K. M., Bunce, M., Ngai, J. L. F., Teo, D., Ong, Y. W., Barouch, D. H., Allsop, C. E. M., et al. (1995) · Tissue Antigens · doi:10.1111/j.1399-0039.1995.tb02444.x · Cited by 142
Bieganowska, K. D., Höllsberg, P., Buckle, G. J., Lim, D., Greten, T. F., Schneck, J. P., Altman, J. D., Jacobson, S., Ledis, S. L., Hanchard, B., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1765 · Cited by 134
Ha, P., Schwarz, S. L., Wunderlich, J. R., & Rosenberg, S. A. (1998) · PubMed · Cited by 110
Self-citationClonal deletion of thymocytes as a tumor escape mechanism
Lauritzsen, G. F., Hofgaard, P. O., Schenck, K., & Bogen, B. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981005)78:2<216::aid-ijc16>3.0.co;2-8 · Cited by 67
Cited by
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
CD4 cells can be more efficient at tumor rejection than CD8 cells
Perez-Diez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 437
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., & Anichini, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.805 · Cited by 401
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R. M., Marincola, F. M., Leitman, S. F., Seipp, C. A., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00007 · Cited by 357
Self-citationPriming of naive T cells inside tumors leads to eradication of established tumors
Yu, P., Lee, Y., Liu, W., Chin, R. K., Wang, J., Wang, Y., Schietinger, A., Philip, M., Schreiber, H., & Fu, Y.-X. (2004) · Nature Immunology · doi:10.1038/ni1029 · Cited by 356
Metadata
- Authors
- Lee, K.-H., Wang, E., Nielsen, M.-B., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S. M., Rosenberg, S. A., & Marincola, F. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-12-01
- Volume
- 163
- Issue
- 11
- Pages
- 6292-6300
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2126061030
- Cited by
- 285
- References
- 35
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.